# EXHIBIT 33

### Case 3:16-md-02741-VC Document 649-3 Filed 10/27/17 Page 2 of 6

# Monsanto Manuscript Clearance Form Global Regulatory

NOTE: this form needs to be completed and submitted for review at least 4 weeks prior to manuscript submission and a minimum of 2 weeks prior to abstract/presentation submission

Questions regarding completion of this form can be directed to Jeanna Graf (4-2011) or Kevin Glenn (4-4242)

	Date: 2/29/2012	
Please indicate type of publication: Manuscript 🔲 C	onference/meeting presentation  Abstract	
Has this information been publicly disclosed previously? manuscript reviews glyphosate genotoxicity (2000) review (If the information has previously been published, no need to it	publications since the Williams et al	
Title: Review of Genotoxicity of Glyphosate a	nd Glyphosate Based Formulations	
Author(s): David Saltmiras, Larry Kier (consultant)		
Author Handling Correspondence: David Saltmiras	Mail Zone: C1NA Phone: 4-8856	
is this related to a Monsanto collaboration? 🔲 No 🔘 🕆	fes If yes, Other	
Meeting Date & Location at which Manuscript will be prese	ented:	
Journal Submitted To: Reg. Toxicol. Pharmacol.		

Lead Author's Comments: (Please provide information on <u>purpose of presentation/publication</u> and any relevant patents or manuscript disclosures.) This manuscript provide a comprehensive quality check on the large number of genotoxicity publications on glyphosate since the Williams et al. (2000) glyphosate toxicology review manuscript. This work falls under the scope of the EU Glyphosate Task Force and will be a valuable resource in future product defense against claims that glyphosate is mutagenic or genotoxic.

February 28, 2012 Regulatory MCF Page 1 of 5

## Case 3:16-md-02741-VC Document 649-3 Filed 10/27/17 Page 3 of 6

Title: Review of Genotoxicity of Glyphosate and Glyphosate Based Formulations

Author Material Transfer Agreement Statement: (Please refer questions to a patent attorney.) I have reviewed the material transfer and data disclosure requirements of the proposed journal and have discussed any such requirements with my direct supervisor. I ensure that when I submit this manuscript, the journal either does not or will not in this instance require Monsanto to provide restricted plasmids or other materials referenced in our manuscript, or that I will obtain legal approval for any such materials prior to submission of this paper.

I have reviewed that the appropriate individuals that have contributed substantial, direct, intellectual work to this manuscript/presentation are included as authors, and other significant contributors have been appropriately acknowledged.

1211

REQUESTOR'S SIGNATURE:

Reviewer: Please review, sign, and return.			
Reviewer	Approval Signature	Date	
Program Lead, Tech Center	W 211.	10/2.15	
John Vicini, C1NA, (W.Blackden)	1941 M	3/9/2012	
Center Lead *	/ ' /	,	
Nordine Cheikh, C3NA, (J.Graf)			
Regulatory Team Lead (Crop/Chem)		0,000,000	
Chemistry; Susan Martino-Catt C3NA (L. Billadeau)			
Crop/ChemTeam Lead Not Applicable	99,000,000,000,000,000,000,000,000,000,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Regulatory Law	***************************************		
Not Applicable			
Regulatory Law (Add'l Reviewer)			
Brandon Neuschafer, E1NH (J. Wardlow)			
Regulatory Scientific Affairs	WOOLAND	<b>0</b>	
Eric Sachs, C3NA, (J. Graf)			
Biotechnology	000000000000000000000000000000000000000		
Not Applicable			
Patent Scientist:	200000000000000000000000000000000000000		
Not Applicable			
Patent Scientist (Add'l Reviewer)			
Not Applicable			
Patent Attorney	300000000000000000000000000000000000000	***************************************	
Not Applicable			
Patent Attorney (Add'l Reviewer)			
Not Applicable			
Regulatory Regional Lead 🎁	9-0000000000000000000000000000000000000	300000000000000000000000000000000000000	
Not Applicable			
Additional Reviewer:	0/000000000		
Other:			

Requestor must send an email message as well as the manuscript clearance form to the administrative assistant of the selected Lead.

\*Center Lead: Please add any other Program Leads that should be included in the review process, and choose "not applicable" for any reviewers that should not be included.

\*\*To be selected when involving samples / data from regional investigators.

February 28, 2012

Regulatory MCF

Page 2 of 5

Requestor must first collate all the signed pages and then send them to Gracie Williams, BB1B (Chesterfield Valley).

February 28, 2012 Regulatory MCF Page 3 of 5

# Monsanto Manuscript Clearance Reviewer Guidelines Form Global Regulatory

**Reviewers:** Please complete your review of this manuscript within 7 working days (abstract/presentation) and 21 working days (publication/manuscript). If timely review is not possible, please communicate this to the lead author within 2 – 3 days of receipt of this MCF indicating a delegate within your organization that can perform the review. Also, please note, reviews are being completed **concurrently**, not sequentially.

#### Program Lead, Tech Center (TC)

Determine if this is the first TC publication on this trait or MON # and that the publication follows past TC practices with earlier Monsanto publications. Ensure that the scientific conclusions (e.g. of compositional equivalence, natural variability) are justified by presented data. Ensure that individuals that have contributed substantial, direct, intellectual work to this manuscript are included as authors and other significant contributions are appropriately acknowledged.

#### Center Lead

Determine that the scientific conclusions are clearly stated and supported by the data. Review assessment of the TC Program Lead (if available). Determine if other TC representatives need to review and provide additional scientific insights and input. Ensure that individuals that have contributed substantial, direct, intellectual work to this manuscript are included as authors and other significant contributions are appropriately acknowledged.

#### Regulatory Team Lead (Crop/Chem)

Ensure that descriptions of MOA, product concepts, etc. are consistent with Product Core Team (PCT) standards, any prior Biotechnology communications, submission documents, etc. Ensure that the manuscript is consistent with the Regulatory and Biotechnology publication strategy.

#### Crop/Chem Team Lead

Ensure that descriptions of MOA, product concepts, etc. are consistent with any prior Biotechnology communications, PCT standards or submissions of trait or MON #. Ensure that the manuscript is consistent with the Regulatory and Biotechnology publication strategy. Confirm that publication contains no comparative assessments or statements between different MONs and that any reference to other MONs is accurate and consistent with prior communications.

#### Regulatory Law

Ensure that publication of MON # (or other invention) is legal and does not compromise Monsanto FTO.

#### Regulatory Scientific Affairs

Ensure that descriptions of MOA, product concepts are consistent with prior communications of trait or MON #. Ensure that the manuscript is consistent with the Regulatory and Biotechnology publication strategy. Ensure that any policy statements or implications are consistent with both Regulatory strategies and scientific outreach efforts.

#### Biotechnology

Ensure that descriptions of MOA, gene sequence, product concepts, etc. are consistent with any prior Biotechnology communications or publications on MON # or related biotech traits. Ensure that the manuscript is consistent with the Regulatory and Biotechnology publication strategy.

#### **Patent Scientist**

Determine that all relevant patents related to MON # are fully in place. Ensure publication does not impact right of Monsanto to make, use, or sell the claimed invention or MON #. Ensure there are no statements or assessments that could result in a loss of IP.

#### **Patent Attorney**

Determine if any patents related to MON # are fully in place. Ensure publication does not impact right of Monsanto to make, use, or sell the claimed invention or MON # or a limited period of time. Ensure there are no statements or assessments that could result in a loss of IP. Confirm assessment of patent scientists.

#### Regulatory Regional Lead

Ensure that the manuscript is consistent with the regional Regulatory strategy. Ensure that individuals that have contributed substantial, direct, intellectual work to this manuscript are included as authors and other significant contributions are appropriately acknowledged.

February 28, 2012 Regulatory MCF Page 4 of 5